Rare Disease Feature: First FDA-Approved Treatment for Eosinophilic Esophagitis Has Roots in NIAID-Funded Research

NIAID grantee's research uncovered the molecular cause of EoE.

Friday, September 16, 2022 First FDA-Approved Treatment for Eosinophilic Esophagitis Has Roots in NIAID-Funded Research Illustration of an eosinophil, a type of white blood cell present in excess in the esophagus of people with eosinophilic esophagitis. Credit: NIAID The first FDA approval of a treatment for eosinophilic esophagitis (EoE) marked a vital achievement earlier this year not only for people with the disease, but also for scientists including a NIAID grantee whose research helped lay a foundation for this milestone. In people with EoE, allergic inflammation damages the esophagus and prevents it from working properly, making swallowing even small amounts of food an often painful and worrisome choking experience. NIAID funding enabled Dr. Marc E. Rothenberg at Cincinnati Children's in Ohio to conduct basic and preclinical research starting in 1999 that uncovered the molecular cause of EoE. This finding suggested the type of drug needed to treat the disorder. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107